Our study emphasizes the additional stratification for patients of synucleinopathy or tauopathy diseases co-occurence, who could be excluded or placed in a different group in clinical trial exclusion for trials targeting only tau or synuclein. This evidence concerns the gene SNCA and synucleinopathy.